Drug Trial Radar · NCT02279160
Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
Last checked: Nov 19, 2026Latest source record: Jul 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
61
Actual
Start
Dec 2014
Primary completion
Jun 2017
Study completion Jun 2017
Sponsor
- Lead sponsor
- United TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 30, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study was conducted as a placebo-controlled, randomized, 22-week double-blind study which included a dose titration period. An additional transition period occurred for those patients who elected to enroll into the open-label extension study, APD811-007. A total of 61 patients with PAH were enrolled.
Conditions
- Pulmonary Arterial Hypertension
Interventions
APD811Drug
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Pulmonary Vascular Resistance (PVR)Time frame: Baseline and 22 Weeks
- Change From Baseline in 6-minute Walk Distance (6MWD) in Patients With PAHTime frame: Baseline and 22 Weeks
Locations
35 sites in 9 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Cedars-Sinai Medical Center
Los Angeles, California
UC Davis Medical Center
Sacramento, California
UCLA Medical Center
Torrance, California
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Maryland
Baltimore, Maryland
Boston University Medical Center
Boston, Massachusetts
University of Cincinnati
Cincinnati, Ohio
Ohio State University Medical Center
Columbus, Ohio
University of Pittsburg Medical Center
Pittsburgh, Pennsylvania
UT Southwestern
Dallas, Texas
University of Texas, Houston Center for Clinical and Translational Sciences
Houston, Texas
The Prince Charles Hospital
Chermside, Australia
St Vincent's Hospital
Darlinghurst, Australia
St Vincent's Hospital
Fitzroy, Australia
Royal Hobart Hospital
Hobart, Australia
Fiona Stanley Hospital
Murdoch, Australia
"Многопрофилната болница за активно лечение "Национална кардиологична болница "" ЕАД
Sofia, Bulgaria
Многопрофилна болница за активно лечение "Света Анна" София АД, Клиника по кардиология
Sofia, Bulgaria
II. interní klinika - klinika kardiologie a angiologie, 1. lékařská fakulta, Univerzita Karlova v Praze a Všeobecná fakultní nemocnice v Praze
Prague, Czechia
Gottsegen György Országos Kardiologiai Intézet, Felnőtt Kardiológia
Budapest, Hungary
Semmelweis Egyetem Pulmonológiai Klinika
Budapest, Hungary
Pécsi Tudományegyetem Klinikai Központ, Szívgyógyászati Klinika
Pécs, Hungary
Uniwersytecki Szpital Kliniczny w Białymstoku
Bialystok, Poland
Krakowski Szpital Specjalistyczny im. Jana Pawła II w Krakowie
Krakow, Poland
Wojewódzki Szpital Specjalistyczny im. W. Biegańskiego w Łodzi
Lodz, Poland
Institutul de Urgență pentru Boli Cardiovasculare, Secția Clinică Cardiologie III
Bucharest, Romania
Institutul de Pneumoftiziologie "Marius Nasta", Secția Clinică Pneumoftiziologie IV
Bucharest, Romania
Spitalul Clinic de Boli Infectioase si Pneumoftiziologie, Sectia Clinica Pneumologie II
Timișoara, Romania
Klinički Centar Srbije (KCS), Klinika za kardiologiju
Belgrade, Serbia
Kliničko-bolnički centar (KBC) Zemun,Klinika za internu medicinu,Sluzba kardiologije
Belgrade, Serbia
Institut za plućne bolesti Vojvodine Sremska Kamenica (IPBVSK),
Kamenitz, Serbia
Hospital Universitari General Vall d'Hebron, Servicio de Neumología
Barcelona, Spain
Hospital Clinic de Barcelona, Departamento de Pneumologia
Barcelona, Spain
Hospital 12 de Octubre, Departamento de Cardiologia
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.